[1]
H. Nyambe, A. Santoso, N. A. Tabri, H. Iskandar, M. Ilyas, and E. P. . Wiriyansyah, “The survival rate comparison of non small cell lung carcinoma patients who are given by epidermal growth factor receptor-tyrosin kinase inhibitor and those given by first-line chemotherapy treatment”, NMSJ, vol. 6, no. 2, pp. 103–115, Jan. 2022.